BUZZ-Rezolute rises as FDA lifts partial clinical hold on blood sugar treatment

Reuters09-09

** Shares of drug developer Rezolute rise 13.3% to $4.93 premarket

** U.S. FDA removes partial clinical holds on drug RZ358, also known as ersodetug - RZLT

** Drug being studied as a treatment for low blood sugar caused by genetic disorder called congenital hyperinsulinism

** Co will now start preparation for including U.S. participants in late-stage trial

** RZLT expects U.S. enrollment to begin in early 2025 and data in H2 2025

** Congenital hyperinsulinism is a rare disease in which beta cells of pancreas secrete too much insulin

** Co's stock up ~338% YTD as of last close

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment